10-K - Imunon, Inc. | StockGist

AI Analysis

AI-generated analysis. Always verify with the original filing.

Imunon narrowed operating and net losses in FY2025 through disciplined cost management including lower employee and consulting expenses, but EPS deteriorated sharply and cash burn persists amid clinical development demands and liquidity constraints.

Key Takeaways

1Operating income improved 23.4% to -$14.7M from -$19.1M as losses narrowed from cost discipline.

2Net income loss reduced 22.2% to -$14.5M from -$18.6M, reflecting better expense control.

3Diluted EPS was -$6.83, worsening 321.6% from -$1.62 due to share count changes.

4Net cash used in operating activities was -$13.9M, improved from prior year -$18.9M.

Key Financial Metrics

EPS

$-6.83

-321.6%

Net Income

-$14.5M

22.2%

free cash flow

-$14.2M

Operating Income

-$14.7M

23.4%